Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Post-Acute and Chronic Post-COVID-19 Syndrome: A Phase I/II Clinical Trial

NCT05116761 is registered in ClinicalTrials.gov with Direct Biologics, LLC as lead sponsor.

NCT NCT05116761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05116761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Post-Acute and Chronic Post-COVID-19 Syndrome: A Phase I/II Clinical Trial
Lead sponsor
Direct Biologics, LLC
Phase
Phase 1/2
Overall status
Withdrawn
Start date
November 30, 2024
Completion date
December 31, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, dyspnea, postviral syndrome